SlideShare a Scribd company logo
Merck KGaA
Darmstadt, Germany
Marine Maszelin, EMEA Process Development Scientist
Partner4Biotech Genopole, June 18, 2020
Design and Scale Up
Normal Flow
Filtration
01
02
03
04
Agenda
2
What is Filtration?
Filter Capacity and Fouling Models
Sizing Approach
Scale Up Considerations
3
Tangential Flow FiltrationNormal Flow Filtration
What is Filtration?
Two different approaches
Pressure driven separation process that uses (membrane) filters to separate components
in a liquid (or suspension) based on their size
Two types of filtration
Filtratefluxrate
Volume filtered
Filtratefluxrate
Volume filtered
4
Normal Flow Filtration (NFF)
1 2
3
4
Cartridge or
“Dead-ended” Filtration
Flow is perpendicular
to the filter media
All fluid passes
through the media
Particles are retained
in/on filter
Examples:
 Clarification, prefiltration
 Bioburden reduction, sterilizing filtration, viral clearance filtration
5
Where are the Normal Flow Filters in my BioPharm Process?
Cell culture
supplements, Media
prep and Mixing
Pre-filtration Bioburden reduction
Bioburden reduction
Bioburden
reduction Bioburden reduction,
aggregate removal,
diafiltration…
Bioreactor
Clarification
Protein A
Chrom
Virus inactivationCation exchange
Chrom
Anion exchange
Chrom
Virus filtration Concentration
Diafiltration
Final Formulation Sterile filtration Final Fill
What happens when a filter blocks?
Flow rate goes down
- May drop below the required flow rate (i.e. filling machine)
Pressure goes up
- May exceed the system differential pressure capabilities
- Cartridge or tubing / fittings
Particles may "bleed" through the filter
- Contaminates / blocks the downstream cartridges
The cost of filtration changes
- Time, product & cartridge cost included
- System should be shut down & cartridge(s) changed
6
1
2
3
4
01
02
03
04
Agenda
7
What is Filtration?
Filter Capacity and Fouling Models
Sizing Approach
Scale Up Considerations
During filtration particles capture could result in:
 Filter plugging (increase resistance to flow)
 Saturation of filter membrane
 The two events can affect process
Filtration should be stopped before:
 A defined time frame
 Reaching a certain filtrate flow
 Impacting product yield
 Contaminants passage
Filter capacity is the volume filtered just before this point
 It depends on filter retention mechanisms
How to Define Filter Capacity?
 Size exclusion
 Sieving (surface)
 Capture (depth)
 Adsorption
 Attraction forces
between particles and media
 Electrostatic / Hydrophobic interactions
/ Zeta potential
 Size independent
 Mechanism related to
 Particle type
 Filter media and structure
Particle Retention Modes
9
DEPTH FILTERS
High capacity
€
SURFACE FILTER / PRE-FILTER
Good efficiency
€ €
MEMBRANE FILTER
Total security
€ € €
Three Main Filter Families
11
 Porous layer of tough particles on the filter
 Liquid go through the filtration cake
− Filtration cake thickness increase is directly proportional
to filter upstream pressure
 Common for primary clarification or coarse filtration
− Example: resin, fines, diatomaceous earth filtration…
Cake Filtration
12
 Impermeable layer of deformable particles on the
filter
 Fluid cannot go through the filter
− Quick and brutal increase of filter upstream pressure
 Common when no pre-filter is used (or insufficient),
or when deformable particles are slightly bigger
than filter pore sizes
− Examples: colloid fluids (cell cultures, serum…)
Complete Pore Blocking
13
 Progressive accumulation of particles in the filter
− Tough or deformable particles
 Filtrate flux gradually decays
− Or slight increase of filter upstream pressure
 The most common fouling model for biopharmaceutical fluids
− Surface filters or membrane filters
Gradual Fouling Model
14
Fouling Models
Complete
Cake
Gradual
DP
Time
Cake
Gradual
 Gradual pore plugging
 Complete pore plugging
 Cake filtration
Choose a Sizing Method
Pmax™ method
Testtype
Adsorption Complete
pore
plugging
Cake Gradual
pore
plugging
Constant
pressure
Constant
flow
Vmax™
method
Tmax
method
Retention / Fouling mechanism
Turbidity increases
during filtration
Pressure drop increases during
filtration
Flux decay increases during filtration
15
01
02
03
04
Agenda
16
What is Filtration?
Filter Capacity and Fouling Models
Sizing Approach
Scale Up Considerations
17
 Sizing tool for surface and membrane filters
 Fast test under constant pressure
 Based on gradual pore fouling model
 Particles are smaller than filter pore size and gradually plugged the filter
 Monitoring of filtrate flux decay during the test
 Vmax™ value is the theoretical maximum amount of product that can be filtered before the
membrane is totally plugged (i.e. the filtration flow rate becomes null)
 Happens when t→ 
What is Vmax™ Methodology?
time (min.)
Traditional Flow Decay
0
2
4
6
8
10
12
0 10 20 30 40 50 60
t/V(min/L)
Vmax
Publication: ”Forrest Badmington, Randy Wilkins, Michael Payne, and Ephraim S. Honig. Vmax testing for Practical
Microfiltration Train Scale-Up in Biopharmaceutical Processing, Pharmaceutical Technology, September 1995, p64-76.”
Vmax™ Method: Test Procedure
Constant pressure
filtration flow rate
decreases as
pores are blocked
t/(V/Area)
t
1/Qi
1/Vmax™
Qi
Volume per area
V/Area
Time, t
≈
∞
Vmax™
Compressed
gas
Test
filter
Pressure
vessel
t / (V/Area) = At + B
B = intercept = 1/Qi
A= slope=1/Vmax™
After bleeding the filter, the product is pushed at constant pressure
through the filter.
Data are collected during 10-30 min:
 Cumulated volume of filtrate (V)
 Time (t)
18
Vmax™ Method: Capacity Range
>5000 L/m² High capacity / low fouling fluid
ex: buffers
250-5000 L/m² Moderate capacity / moderately fouling
fluid
ex: most solutions after
adequate prefiltration
<250 L/m² Low capacity / very fouling fluid
ex: unfiltered serum
19
Vmax™ Method: Sizing Scenarios
max
min
V
V
A B
=
Case 1. Only VB (Batch Volume) is known
Bi
BB
tJ
V
V
V
A

+=
max
min
Case 2. VB (Batch Volume) and tB (Batch time) are known
Case 3. VB (Batch Volume), tB (Batch time) & Jmin (minimum flow) are known
Iterative calculation (trial/error)
Case 4. Sizing by flux (non fouling fluids)
meanb
b
Jt
V
A
x
min =
minmaxmin
min
1
AV
V
AJ
J B
i 
=

−
20
Vmax™ Method
Advantages
 Predictive method: no need to test until max capacity is reached
− Quick testing (15-30 min; buffers Kbuf better option)
− Low fluid volume required
− Allows for multiple testing (screening method)
 Powerful analysis tool
− 2 parameters for sizing (permeability + Vmax™)
− 4 scenarios for sizing
Limits
 Only applicable to gradual pore plugging
− Not applicable to depth filters
21
22
 Can be used for all filter types (depth, surface and membrane) but specifically used for
depth filters
 Non-predictive experiment
 Based on real filter capacity
 Can be used for all the fouling models
 Monitoring of filter upstream pressure increase (Pmax™) and/or filtrate trubidity (Tmax™) during
the experiments
 Pmax™/Tmax™ is the amount of product that can be filtered before a defined upstream
pressure or a defined filtrate turbidity is reached
What is Pmax™/Tmax™ Methodology?
Constant flow experiment: Pmax™ or/and Tmax™
- Constant residence time (adsorption)
- Procedure
Equipment: pump, pressure gauge, balance
Set-up:
Data: pressure and feed flow monitoring, measure of contaminants passage (turbidity, OD550nm or
OD280nm)
Pmax™/Tmax™ : Testing Depth Filters
23
Pmax™ /Tmax™ methodology
Filter capacity is reached when:
- Trial pressure = pressure endpoint (Pmax™)
OR
- Filtrate turbidity breakthrough is observed (Tmax™)
Turbidity(NTU)
Pressure(psi)
Filtrate volume (L/m²)
Capacitiy at
small-scale
Sizing
Manufacturing
parameters
24
Pmax™ Method: Capacity Range
> >350 L/m2 High capacity
ex: supernatant CHO cells after
centrifug.
100 - 350 L/m2 Moderate capacity
ex: permeate after TFF
microfiltration
<<100 L/m2 Low capacity
ex: high density cell culture
25
Pmax™/Tmax™
Advantages
 Applicable independently from retention/ plugging mechanism
− Analysis of empirical data
− No mathematical model
Limits
 No predictive model: test needs to be performed until max capacity
− Need for sufficient product volume
− Test time can be long : 2-6h (→ several parallel filtrations)
26
Rule of thumb is 1.3-1.5X safety factor, but…
It depends on:
 Quantity and quality of data
 Expected variability of feed solution
 Expected variability of filter
 Available filter sizes
 Scale-up factor
Sizing and Safety Factor
Minimal
area
Process
area
minA
A
factorSafety
process
=
27
Publication: ”Herb Lutz. Rationally defined safety factors for filter sizing, Journal of Membrane Science, Volume 341 (2009), p268–278.”
01
02
03
04
Agenda
28
What is Filtration?
Filter Capacity and Fouling Models
Sizing Approach
Scale Up Considerations
29
Filtration Train Development Strategy
3. Simulation trials
Objective: sizing
confirmation with process
conditions
2. Screening trials
Objective: identify the best
filtration train and size it
quickly
1. Test filter
identification
Filter to be evaluated
Depth filters:
Tests Pmax™/Tmax™
Final process with
pump:
Pmax™ mode
simulation
Surface/membrane
filters:
Tests Vmax™
Final process under
constant pressure:
Vmax™ mode
simulation
 Filters are tested
separately (not as a
train).
 Feedstock quality is
uniform during
filtration.
 Pressure is uniform
(Vmax™ test).
During screening
tests…
 Check filter performances
(capacity and filtrate
quality) in process
operating final conditions.
 Check Safety Factor for
sizing (adjust if needed).
 Prepare Scale Up-Down
(max factor 100x).
 Generate filtrate for DSP
steps design.
Simulation
trials
 Filters are ‘in-line’
(filtration train).
 Feedstock quality varies
if upstream filters foul.
 Pressure repartition can
vary for each filtration
step.
 Flows and feeding
methods
(pump/pressure) can
differ from those applied
during testing.
During
Manufacturing…
Objectives
30
How to Minimize Filtration Problems
Use low initial differential pressure
− ~1-2 psid or ~0.1 bar
Monitor & change on differential
pressure
 Biological fluids
− Depth Filters : 10 - 15 psid (0.7-1
bar)
− Surface Filters & Membrane Filters :
30 - 50 psid (2-3.3 bar)
− When filter specification is exceeded
Ensure adequate pressure from
pressure source (pump / pressure vessel)
31
1
2
3
Normal Flow Filtration: Design and Scale up
Take away
NFF Design
and Scale-
up |
Genopole |
18.06.2019 32
Process
Requirements
Screening
Bench Scale
Process Simulation
Bench/Pilot Scale
Implementation
Large Scale
Scale Down
Strategy Troubleshooting
Plan your visit today.
EMDMillipore.com/mlab
The vibrant M and M Lab are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective
owners. Detailed information on trademarks is available via publicly accessible resources.
© 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

More Related Content

What's hot

Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceParvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Merck Life Sciences
 
Introduction to Tangential Flow Filtration (TFF)
Introduction to Tangential Flow Filtration (TFF)Introduction to Tangential Flow Filtration (TFF)
Introduction to Tangential Flow Filtration (TFF)
Merck Life Sciences
 
Scale-up of high area filters for microfiltration of biological fluids - Poin...
Scale-up of high area filters for microfiltration of biological fluids - Poin...Scale-up of high area filters for microfiltration of biological fluids - Poin...
Scale-up of high area filters for microfiltration of biological fluids - Poin...
MilliporeSigma
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...
Merck Life Sciences
 
Validation of Tangential Flow Filtration in Biotech Processes
Validation of Tangential Flow Filtration in Biotech ProcessesValidation of Tangential Flow Filtration in Biotech Processes
Validation of Tangential Flow Filtration in Biotech Processes
Merck Life Sciences
 
Presentation1 tff
Presentation1 tffPresentation1 tff
Presentation1 tff
chauhan suraj
 
Process Scale Chromatography
Process Scale ChromatographyProcess Scale Chromatography
Process Scale Chromatography
Merck Life Sciences
 
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
Merck Life Sciences
 
Quality by Design Principles Applied to Sterilizing Filtration by Michael Payne
Quality by Design Principles Applied to Sterilizing Filtration by Michael PayneQuality by Design Principles Applied to Sterilizing Filtration by Michael Payne
Quality by Design Principles Applied to Sterilizing Filtration by Michael Payne
Merck Life Sciences
 
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
Merck Life Sciences
 
Filter Validation and Regulatory aspects
Filter Validation and Regulatory aspectsFilter Validation and Regulatory aspects
Filter Validation and Regulatory aspects
bala murugan
 
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
Single-Pass Tangential Flow Filtration (SPTFF) Theory and PracticeSingle-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
MilliporeSigma
 
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
Merck Life Sciences
 
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
Single-Pass Tangential Flow Filtration (SPTFF) Theory and PracticeSingle-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
Merck Life Sciences
 
Cross Flow or Tangential Flow Membrane Filtration (TFF) to Enable High Solids...
Cross Flow or Tangential Flow Membrane Filtration (TFF) to Enable High Solids...Cross Flow or Tangential Flow Membrane Filtration (TFF) to Enable High Solids...
Cross Flow or Tangential Flow Membrane Filtration (TFF) to Enable High Solids...
njcnews777
 
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationEU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
Merck Life Sciences
 
Single-Use Tangential Flow Filtration for Closed Processing
Single-Use Tangential Flow Filtration for Closed ProcessingSingle-Use Tangential Flow Filtration for Closed Processing
Single-Use Tangential Flow Filtration for Closed Processing
Merck Life Sciences
 
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
MilliporeSigma
 
Millipak® Final Fill Filters
Millipak® Final Fill FiltersMillipak® Final Fill Filters
Millipak® Final Fill Filters
MilliporeSigma
 
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...
Merck Life Sciences
 

What's hot (20)

Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceParvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
 
Introduction to Tangential Flow Filtration (TFF)
Introduction to Tangential Flow Filtration (TFF)Introduction to Tangential Flow Filtration (TFF)
Introduction to Tangential Flow Filtration (TFF)
 
Scale-up of high area filters for microfiltration of biological fluids - Poin...
Scale-up of high area filters for microfiltration of biological fluids - Poin...Scale-up of high area filters for microfiltration of biological fluids - Poin...
Scale-up of high area filters for microfiltration of biological fluids - Poin...
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...
 
Validation of Tangential Flow Filtration in Biotech Processes
Validation of Tangential Flow Filtration in Biotech ProcessesValidation of Tangential Flow Filtration in Biotech Processes
Validation of Tangential Flow Filtration in Biotech Processes
 
Presentation1 tff
Presentation1 tffPresentation1 tff
Presentation1 tff
 
Process Scale Chromatography
Process Scale ChromatographyProcess Scale Chromatography
Process Scale Chromatography
 
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
 
Quality by Design Principles Applied to Sterilizing Filtration by Michael Payne
Quality by Design Principles Applied to Sterilizing Filtration by Michael PayneQuality by Design Principles Applied to Sterilizing Filtration by Michael Payne
Quality by Design Principles Applied to Sterilizing Filtration by Michael Payne
 
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
 
Filter Validation and Regulatory aspects
Filter Validation and Regulatory aspectsFilter Validation and Regulatory aspects
Filter Validation and Regulatory aspects
 
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
Single-Pass Tangential Flow Filtration (SPTFF) Theory and PracticeSingle-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
 
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
 
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
Single-Pass Tangential Flow Filtration (SPTFF) Theory and PracticeSingle-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
 
Cross Flow or Tangential Flow Membrane Filtration (TFF) to Enable High Solids...
Cross Flow or Tangential Flow Membrane Filtration (TFF) to Enable High Solids...Cross Flow or Tangential Flow Membrane Filtration (TFF) to Enable High Solids...
Cross Flow or Tangential Flow Membrane Filtration (TFF) to Enable High Solids...
 
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationEU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
 
Single-Use Tangential Flow Filtration for Closed Processing
Single-Use Tangential Flow Filtration for Closed ProcessingSingle-Use Tangential Flow Filtration for Closed Processing
Single-Use Tangential Flow Filtration for Closed Processing
 
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
 
Millipak® Final Fill Filters
Millipak® Final Fill FiltersMillipak® Final Fill Filters
Millipak® Final Fill Filters
 
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...
 

Similar to Normal Flow Filtration: Design and Scale Up

66 membrane filter integrity test
66 membrane filter integrity test66 membrane filter integrity test
66 membrane filter integrity test
Kethana Nellore
 
Single-Use Tangential Flow Filtration for Closed Processing
Single-Use Tangential Flow Filtration for Closed ProcessingSingle-Use Tangential Flow Filtration for Closed Processing
Single-Use Tangential Flow Filtration for Closed Processing
MilliporeSigma
 
Dhruti Avlani - TLC & HPTLC
Dhruti Avlani - TLC & HPTLCDhruti Avlani - TLC & HPTLC
Dhruti Avlani - TLC & HPTLC
DHRUTI AVLANI
 
Filter validation
Filter validationFilter validation
Filter validation
VINOTH R
 
03.pdf
03.pdf03.pdf
03.pdf
Carki1
 
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
Filtration Strategies for Optimal Development and Purification of a FMD Virus...Filtration Strategies for Optimal Development and Purification of a FMD Virus...
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
MilliporeSigma
 
6.STERILIZATION BY FILTRATION.ppt
6.STERILIZATION BY FILTRATION.ppt6.STERILIZATION BY FILTRATION.ppt
6.STERILIZATION BY FILTRATION.ppt
AbwoneKenneth
 
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
Filtration Strategies for Optimal Development and Purification of a FMD Virus...Filtration Strategies for Optimal Development and Purification of a FMD Virus...
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
Merck Life Sciences
 
Clarification
ClarificationClarification
Clarification
Mohammed AL-Marzoogee
 
Objectives, applications & Theories in FILTRATION
Objectives, applications & Theories in FILTRATIONObjectives, applications & Theories in FILTRATION
Objectives, applications & Theories in FILTRATION
AkankshaPatel55
 
Filtrasi.ppt
Filtrasi.pptFiltrasi.ppt
Filtrasi.ppt
fatma sari
 
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationEU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
MilliporeSigma
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Merck Life Sciences
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
MilliporeSigma
 
Mechanical unit operations 19_09.pptx
Mechanical unit operations 19_09.pptxMechanical unit operations 19_09.pptx
Mechanical unit operations 19_09.pptx
BhavikkumarBhupendra
 
Filtration.pdf
Filtration.pdfFiltration.pdf
Filtration.pdf
AminaButt14
 
Filtration
FiltrationFiltration
Filtration
Tapeshwar Yadav
 
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceParvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
MilliporeSigma
 
Filtration.pptx
Filtration.pptxFiltration.pptx
Filtration.pptx
HeeraKaremore
 
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
MilliporeSigma
 

Similar to Normal Flow Filtration: Design and Scale Up (20)

66 membrane filter integrity test
66 membrane filter integrity test66 membrane filter integrity test
66 membrane filter integrity test
 
Single-Use Tangential Flow Filtration for Closed Processing
Single-Use Tangential Flow Filtration for Closed ProcessingSingle-Use Tangential Flow Filtration for Closed Processing
Single-Use Tangential Flow Filtration for Closed Processing
 
Dhruti Avlani - TLC & HPTLC
Dhruti Avlani - TLC & HPTLCDhruti Avlani - TLC & HPTLC
Dhruti Avlani - TLC & HPTLC
 
Filter validation
Filter validationFilter validation
Filter validation
 
03.pdf
03.pdf03.pdf
03.pdf
 
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
Filtration Strategies for Optimal Development and Purification of a FMD Virus...Filtration Strategies for Optimal Development and Purification of a FMD Virus...
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
 
6.STERILIZATION BY FILTRATION.ppt
6.STERILIZATION BY FILTRATION.ppt6.STERILIZATION BY FILTRATION.ppt
6.STERILIZATION BY FILTRATION.ppt
 
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
Filtration Strategies for Optimal Development and Purification of a FMD Virus...Filtration Strategies for Optimal Development and Purification of a FMD Virus...
Filtration Strategies for Optimal Development and Purification of a FMD Virus...
 
Clarification
ClarificationClarification
Clarification
 
Objectives, applications & Theories in FILTRATION
Objectives, applications & Theories in FILTRATIONObjectives, applications & Theories in FILTRATION
Objectives, applications & Theories in FILTRATION
 
Filtrasi.ppt
Filtrasi.pptFiltrasi.ppt
Filtrasi.ppt
 
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationEU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
 
Mechanical unit operations 19_09.pptx
Mechanical unit operations 19_09.pptxMechanical unit operations 19_09.pptx
Mechanical unit operations 19_09.pptx
 
Filtration.pdf
Filtration.pdfFiltration.pdf
Filtration.pdf
 
Filtration
FiltrationFiltration
Filtration
 
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceParvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
 
Filtration.pptx
Filtration.pptxFiltration.pptx
Filtration.pptx
 
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
 

More from MilliporeSigma

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide Alternative
MilliporeSigma
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
MilliporeSigma
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein Purification
MilliporeSigma
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...
MilliporeSigma
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
MilliporeSigma
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
MilliporeSigma
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
MilliporeSigma
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical Audits
MilliporeSigma
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
MilliporeSigma
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapies
MilliporeSigma
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...
MilliporeSigma
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
MilliporeSigma
 
How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?
MilliporeSigma
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
MilliporeSigma
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
MilliporeSigma
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
MilliporeSigma
 
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
MilliporeSigma
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
MilliporeSigma
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...
MilliporeSigma
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC Therapies
MilliporeSigma
 

More from MilliporeSigma (20)

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide Alternative
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein Purification
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical Audits
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapies
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
 
How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
 
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC Therapies
 

Recently uploaded

Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...
rightmanforbloodline
 
CSE presentation 050804-nikhil tandon.ppt
CSE presentation 050804-nikhil tandon.pptCSE presentation 050804-nikhil tandon.ppt
CSE presentation 050804-nikhil tandon.ppt
vattakandyrahoof8
 
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
Media Logic
 
Test bank calculating drug dosages a patient safe approach to nursing and mat...
Test bank calculating drug dosages a patient safe approach to nursing and mat...Test bank calculating drug dosages a patient safe approach to nursing and mat...
Test bank calculating drug dosages a patient safe approach to nursing and mat...
rightmanforbloodline
 
Movies as a mirror of a society, Introduction
Movies as a mirror of a society, IntroductionMovies as a mirror of a society, Introduction
Movies as a mirror of a society, Introduction
medicineseuge
 
PPT DDTK 2 untuk balita dan prasekolah, deteksi dini tumbuh kembang pada anak
PPT DDTK 2 untuk balita dan prasekolah, deteksi dini tumbuh kembang pada anakPPT DDTK 2 untuk balita dan prasekolah, deteksi dini tumbuh kembang pada anak
PPT DDTK 2 untuk balita dan prasekolah, deteksi dini tumbuh kembang pada anak
woelan1
 
Unlimited Short Call Girls Thane ✅ 9833325238 FULL CASH PAYMENT
Unlimited Short Call Girls Thane ✅ 9833325238 FULL CASH PAYMENTUnlimited Short Call Girls Thane ✅ 9833325238 FULL CASH PAYMENT
Unlimited Short Call Girls Thane ✅ 9833325238 FULL CASH PAYMENT
rajesh344555
 
PRESSURE INJURY CARE AND MANAGEMENT FOR HCW
PRESSURE INJURY CARE AND MANAGEMENT FOR HCWPRESSURE INJURY CARE AND MANAGEMENT FOR HCW
PRESSURE INJURY CARE AND MANAGEMENT FOR HCW
dnee1
 
Psychological Safety as a Foundation for Improvement 12-06-24.pdf
Psychological Safety as a Foundation for Improvement 12-06-24.pdfPsychological Safety as a Foundation for Improvement 12-06-24.pdf
Psychological Safety as a Foundation for Improvement 12-06-24.pdf
Healthcare Improvement Support
 
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
DrDevTaneja1
 
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 BathindaBathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
varun0kumar00
 
Health Tech Market Intelligence Prelim Questions -
Health Tech Market Intelligence Prelim Questions -Health Tech Market Intelligence Prelim Questions -
Health Tech Market Intelligence Prelim Questions -
Gokul Rangarajan
 
Sunscreens, IP-I, Dr. M.N.CHISHTI, Asst Prof. Dept of Pharmaceutics, YBCCPA
Sunscreens, IP-I, Dr. M.N.CHISHTI, Asst Prof. Dept of Pharmaceutics, YBCCPASunscreens, IP-I, Dr. M.N.CHISHTI, Asst Prof. Dept of Pharmaceutics, YBCCPA
Sunscreens, IP-I, Dr. M.N.CHISHTI, Asst Prof. Dept of Pharmaceutics, YBCCPA
ssuser555edf
 
EXAMINATION OF HUMAN URINE AND FAECES.pdf
EXAMINATION OF HUMAN URINE AND FAECES.pdfEXAMINATION OF HUMAN URINE AND FAECES.pdf
EXAMINATION OF HUMAN URINE AND FAECES.pdf
Madhusmita Sahoo
 
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Hyderabad Call Girls 7023059433 High Profile Escorts Service HyderabadHyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
garge6804
 
ASSESSMENT OF THE SKIN, HAIR, AND NAILS.pptx
ASSESSMENT OF THE SKIN, HAIR, AND NAILS.pptxASSESSMENT OF THE SKIN, HAIR, AND NAILS.pptx
ASSESSMENT OF THE SKIN, HAIR, AND NAILS.pptx
Rommel Luis III Israel
 
Bashundhara Toiletries Logo Guideline 2024
Bashundhara Toiletries Logo Guideline 2024Bashundhara Toiletries Logo Guideline 2024
Bashundhara Toiletries Logo Guideline 2024
khabri85
 
PPT on Embryological and fetal development
PPT on Embryological and fetal developmentPPT on Embryological and fetal development
PPT on Embryological and fetal development
smileysharma63
 
ASSESSMENT OF THE EYE (1)-Health Assessment.ppt
ASSESSMENT OF THE EYE (1)-Health Assessment.pptASSESSMENT OF THE EYE (1)-Health Assessment.ppt
ASSESSMENT OF THE EYE (1)-Health Assessment.ppt
Rommel Luis III Israel
 
Nursing management of the patient with Tonsillitis PPT
Nursing management of the patient with Tonsillitis PPTNursing management of the patient with Tonsillitis PPT
Nursing management of the patient with Tonsillitis PPT
blessyjannu21
 

Recently uploaded (20)

Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...
 
CSE presentation 050804-nikhil tandon.ppt
CSE presentation 050804-nikhil tandon.pptCSE presentation 050804-nikhil tandon.ppt
CSE presentation 050804-nikhil tandon.ppt
 
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
 
Test bank calculating drug dosages a patient safe approach to nursing and mat...
Test bank calculating drug dosages a patient safe approach to nursing and mat...Test bank calculating drug dosages a patient safe approach to nursing and mat...
Test bank calculating drug dosages a patient safe approach to nursing and mat...
 
Movies as a mirror of a society, Introduction
Movies as a mirror of a society, IntroductionMovies as a mirror of a society, Introduction
Movies as a mirror of a society, Introduction
 
PPT DDTK 2 untuk balita dan prasekolah, deteksi dini tumbuh kembang pada anak
PPT DDTK 2 untuk balita dan prasekolah, deteksi dini tumbuh kembang pada anakPPT DDTK 2 untuk balita dan prasekolah, deteksi dini tumbuh kembang pada anak
PPT DDTK 2 untuk balita dan prasekolah, deteksi dini tumbuh kembang pada anak
 
Unlimited Short Call Girls Thane ✅ 9833325238 FULL CASH PAYMENT
Unlimited Short Call Girls Thane ✅ 9833325238 FULL CASH PAYMENTUnlimited Short Call Girls Thane ✅ 9833325238 FULL CASH PAYMENT
Unlimited Short Call Girls Thane ✅ 9833325238 FULL CASH PAYMENT
 
PRESSURE INJURY CARE AND MANAGEMENT FOR HCW
PRESSURE INJURY CARE AND MANAGEMENT FOR HCWPRESSURE INJURY CARE AND MANAGEMENT FOR HCW
PRESSURE INJURY CARE AND MANAGEMENT FOR HCW
 
Psychological Safety as a Foundation for Improvement 12-06-24.pdf
Psychological Safety as a Foundation for Improvement 12-06-24.pdfPsychological Safety as a Foundation for Improvement 12-06-24.pdf
Psychological Safety as a Foundation for Improvement 12-06-24.pdf
 
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
 
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 BathindaBathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
Bathinda ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 7742996321 ℂ𝕒𝕝𝕝 𝔾𝕚𝕣𝕝𝕤 Bathinda
 
Health Tech Market Intelligence Prelim Questions -
Health Tech Market Intelligence Prelim Questions -Health Tech Market Intelligence Prelim Questions -
Health Tech Market Intelligence Prelim Questions -
 
Sunscreens, IP-I, Dr. M.N.CHISHTI, Asst Prof. Dept of Pharmaceutics, YBCCPA
Sunscreens, IP-I, Dr. M.N.CHISHTI, Asst Prof. Dept of Pharmaceutics, YBCCPASunscreens, IP-I, Dr. M.N.CHISHTI, Asst Prof. Dept of Pharmaceutics, YBCCPA
Sunscreens, IP-I, Dr. M.N.CHISHTI, Asst Prof. Dept of Pharmaceutics, YBCCPA
 
EXAMINATION OF HUMAN URINE AND FAECES.pdf
EXAMINATION OF HUMAN URINE AND FAECES.pdfEXAMINATION OF HUMAN URINE AND FAECES.pdf
EXAMINATION OF HUMAN URINE AND FAECES.pdf
 
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Hyderabad Call Girls 7023059433 High Profile Escorts Service HyderabadHyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
 
ASSESSMENT OF THE SKIN, HAIR, AND NAILS.pptx
ASSESSMENT OF THE SKIN, HAIR, AND NAILS.pptxASSESSMENT OF THE SKIN, HAIR, AND NAILS.pptx
ASSESSMENT OF THE SKIN, HAIR, AND NAILS.pptx
 
Bashundhara Toiletries Logo Guideline 2024
Bashundhara Toiletries Logo Guideline 2024Bashundhara Toiletries Logo Guideline 2024
Bashundhara Toiletries Logo Guideline 2024
 
PPT on Embryological and fetal development
PPT on Embryological and fetal developmentPPT on Embryological and fetal development
PPT on Embryological and fetal development
 
ASSESSMENT OF THE EYE (1)-Health Assessment.ppt
ASSESSMENT OF THE EYE (1)-Health Assessment.pptASSESSMENT OF THE EYE (1)-Health Assessment.ppt
ASSESSMENT OF THE EYE (1)-Health Assessment.ppt
 
Nursing management of the patient with Tonsillitis PPT
Nursing management of the patient with Tonsillitis PPTNursing management of the patient with Tonsillitis PPT
Nursing management of the patient with Tonsillitis PPT
 

Normal Flow Filtration: Design and Scale Up

  • 1. Merck KGaA Darmstadt, Germany Marine Maszelin, EMEA Process Development Scientist Partner4Biotech Genopole, June 18, 2020 Design and Scale Up Normal Flow Filtration
  • 2. 01 02 03 04 Agenda 2 What is Filtration? Filter Capacity and Fouling Models Sizing Approach Scale Up Considerations
  • 3. 3 Tangential Flow FiltrationNormal Flow Filtration What is Filtration? Two different approaches Pressure driven separation process that uses (membrane) filters to separate components in a liquid (or suspension) based on their size Two types of filtration Filtratefluxrate Volume filtered Filtratefluxrate Volume filtered
  • 4. 4 Normal Flow Filtration (NFF) 1 2 3 4 Cartridge or “Dead-ended” Filtration Flow is perpendicular to the filter media All fluid passes through the media Particles are retained in/on filter Examples:  Clarification, prefiltration  Bioburden reduction, sterilizing filtration, viral clearance filtration
  • 5. 5 Where are the Normal Flow Filters in my BioPharm Process? Cell culture supplements, Media prep and Mixing Pre-filtration Bioburden reduction Bioburden reduction Bioburden reduction Bioburden reduction, aggregate removal, diafiltration… Bioreactor Clarification Protein A Chrom Virus inactivationCation exchange Chrom Anion exchange Chrom Virus filtration Concentration Diafiltration Final Formulation Sterile filtration Final Fill
  • 6. What happens when a filter blocks? Flow rate goes down - May drop below the required flow rate (i.e. filling machine) Pressure goes up - May exceed the system differential pressure capabilities - Cartridge or tubing / fittings Particles may "bleed" through the filter - Contaminates / blocks the downstream cartridges The cost of filtration changes - Time, product & cartridge cost included - System should be shut down & cartridge(s) changed 6 1 2 3 4
  • 7. 01 02 03 04 Agenda 7 What is Filtration? Filter Capacity and Fouling Models Sizing Approach Scale Up Considerations
  • 8. During filtration particles capture could result in:  Filter plugging (increase resistance to flow)  Saturation of filter membrane  The two events can affect process Filtration should be stopped before:  A defined time frame  Reaching a certain filtrate flow  Impacting product yield  Contaminants passage Filter capacity is the volume filtered just before this point  It depends on filter retention mechanisms How to Define Filter Capacity?
  • 9.  Size exclusion  Sieving (surface)  Capture (depth)  Adsorption  Attraction forces between particles and media  Electrostatic / Hydrophobic interactions / Zeta potential  Size independent  Mechanism related to  Particle type  Filter media and structure Particle Retention Modes 9
  • 10. DEPTH FILTERS High capacity € SURFACE FILTER / PRE-FILTER Good efficiency € € MEMBRANE FILTER Total security € € € Three Main Filter Families
  • 11. 11  Porous layer of tough particles on the filter  Liquid go through the filtration cake − Filtration cake thickness increase is directly proportional to filter upstream pressure  Common for primary clarification or coarse filtration − Example: resin, fines, diatomaceous earth filtration… Cake Filtration
  • 12. 12  Impermeable layer of deformable particles on the filter  Fluid cannot go through the filter − Quick and brutal increase of filter upstream pressure  Common when no pre-filter is used (or insufficient), or when deformable particles are slightly bigger than filter pore sizes − Examples: colloid fluids (cell cultures, serum…) Complete Pore Blocking
  • 13. 13  Progressive accumulation of particles in the filter − Tough or deformable particles  Filtrate flux gradually decays − Or slight increase of filter upstream pressure  The most common fouling model for biopharmaceutical fluids − Surface filters or membrane filters Gradual Fouling Model
  • 14. 14 Fouling Models Complete Cake Gradual DP Time Cake Gradual  Gradual pore plugging  Complete pore plugging  Cake filtration
  • 15. Choose a Sizing Method Pmax™ method Testtype Adsorption Complete pore plugging Cake Gradual pore plugging Constant pressure Constant flow Vmax™ method Tmax method Retention / Fouling mechanism Turbidity increases during filtration Pressure drop increases during filtration Flux decay increases during filtration 15
  • 16. 01 02 03 04 Agenda 16 What is Filtration? Filter Capacity and Fouling Models Sizing Approach Scale Up Considerations
  • 17. 17  Sizing tool for surface and membrane filters  Fast test under constant pressure  Based on gradual pore fouling model  Particles are smaller than filter pore size and gradually plugged the filter  Monitoring of filtrate flux decay during the test  Vmax™ value is the theoretical maximum amount of product that can be filtered before the membrane is totally plugged (i.e. the filtration flow rate becomes null)  Happens when t→  What is Vmax™ Methodology? time (min.) Traditional Flow Decay 0 2 4 6 8 10 12 0 10 20 30 40 50 60 t/V(min/L) Vmax Publication: ”Forrest Badmington, Randy Wilkins, Michael Payne, and Ephraim S. Honig. Vmax testing for Practical Microfiltration Train Scale-Up in Biopharmaceutical Processing, Pharmaceutical Technology, September 1995, p64-76.”
  • 18. Vmax™ Method: Test Procedure Constant pressure filtration flow rate decreases as pores are blocked t/(V/Area) t 1/Qi 1/Vmax™ Qi Volume per area V/Area Time, t ≈ ∞ Vmax™ Compressed gas Test filter Pressure vessel t / (V/Area) = At + B B = intercept = 1/Qi A= slope=1/Vmax™ After bleeding the filter, the product is pushed at constant pressure through the filter. Data are collected during 10-30 min:  Cumulated volume of filtrate (V)  Time (t) 18
  • 19. Vmax™ Method: Capacity Range >5000 L/m² High capacity / low fouling fluid ex: buffers 250-5000 L/m² Moderate capacity / moderately fouling fluid ex: most solutions after adequate prefiltration <250 L/m² Low capacity / very fouling fluid ex: unfiltered serum 19
  • 20. Vmax™ Method: Sizing Scenarios max min V V A B = Case 1. Only VB (Batch Volume) is known Bi BB tJ V V V A  += max min Case 2. VB (Batch Volume) and tB (Batch time) are known Case 3. VB (Batch Volume), tB (Batch time) & Jmin (minimum flow) are known Iterative calculation (trial/error) Case 4. Sizing by flux (non fouling fluids) meanb b Jt V A x min = minmaxmin min 1 AV V AJ J B i  =  − 20
  • 21. Vmax™ Method Advantages  Predictive method: no need to test until max capacity is reached − Quick testing (15-30 min; buffers Kbuf better option) − Low fluid volume required − Allows for multiple testing (screening method)  Powerful analysis tool − 2 parameters for sizing (permeability + Vmax™) − 4 scenarios for sizing Limits  Only applicable to gradual pore plugging − Not applicable to depth filters 21
  • 22. 22  Can be used for all filter types (depth, surface and membrane) but specifically used for depth filters  Non-predictive experiment  Based on real filter capacity  Can be used for all the fouling models  Monitoring of filter upstream pressure increase (Pmax™) and/or filtrate trubidity (Tmax™) during the experiments  Pmax™/Tmax™ is the amount of product that can be filtered before a defined upstream pressure or a defined filtrate turbidity is reached What is Pmax™/Tmax™ Methodology?
  • 23. Constant flow experiment: Pmax™ or/and Tmax™ - Constant residence time (adsorption) - Procedure Equipment: pump, pressure gauge, balance Set-up: Data: pressure and feed flow monitoring, measure of contaminants passage (turbidity, OD550nm or OD280nm) Pmax™/Tmax™ : Testing Depth Filters 23
  • 24. Pmax™ /Tmax™ methodology Filter capacity is reached when: - Trial pressure = pressure endpoint (Pmax™) OR - Filtrate turbidity breakthrough is observed (Tmax™) Turbidity(NTU) Pressure(psi) Filtrate volume (L/m²) Capacitiy at small-scale Sizing Manufacturing parameters 24
  • 25. Pmax™ Method: Capacity Range > >350 L/m2 High capacity ex: supernatant CHO cells after centrifug. 100 - 350 L/m2 Moderate capacity ex: permeate after TFF microfiltration <<100 L/m2 Low capacity ex: high density cell culture 25
  • 26. Pmax™/Tmax™ Advantages  Applicable independently from retention/ plugging mechanism − Analysis of empirical data − No mathematical model Limits  No predictive model: test needs to be performed until max capacity − Need for sufficient product volume − Test time can be long : 2-6h (→ several parallel filtrations) 26
  • 27. Rule of thumb is 1.3-1.5X safety factor, but… It depends on:  Quantity and quality of data  Expected variability of feed solution  Expected variability of filter  Available filter sizes  Scale-up factor Sizing and Safety Factor Minimal area Process area minA A factorSafety process = 27 Publication: ”Herb Lutz. Rationally defined safety factors for filter sizing, Journal of Membrane Science, Volume 341 (2009), p268–278.”
  • 28. 01 02 03 04 Agenda 28 What is Filtration? Filter Capacity and Fouling Models Sizing Approach Scale Up Considerations
  • 29. 29 Filtration Train Development Strategy 3. Simulation trials Objective: sizing confirmation with process conditions 2. Screening trials Objective: identify the best filtration train and size it quickly 1. Test filter identification Filter to be evaluated Depth filters: Tests Pmax™/Tmax™ Final process with pump: Pmax™ mode simulation Surface/membrane filters: Tests Vmax™ Final process under constant pressure: Vmax™ mode simulation
  • 30.  Filters are tested separately (not as a train).  Feedstock quality is uniform during filtration.  Pressure is uniform (Vmax™ test). During screening tests…  Check filter performances (capacity and filtrate quality) in process operating final conditions.  Check Safety Factor for sizing (adjust if needed).  Prepare Scale Up-Down (max factor 100x).  Generate filtrate for DSP steps design. Simulation trials  Filters are ‘in-line’ (filtration train).  Feedstock quality varies if upstream filters foul.  Pressure repartition can vary for each filtration step.  Flows and feeding methods (pump/pressure) can differ from those applied during testing. During Manufacturing… Objectives 30
  • 31. How to Minimize Filtration Problems Use low initial differential pressure − ~1-2 psid or ~0.1 bar Monitor & change on differential pressure  Biological fluids − Depth Filters : 10 - 15 psid (0.7-1 bar) − Surface Filters & Membrane Filters : 30 - 50 psid (2-3.3 bar) − When filter specification is exceeded Ensure adequate pressure from pressure source (pump / pressure vessel) 31 1 2 3
  • 32. Normal Flow Filtration: Design and Scale up Take away NFF Design and Scale- up | Genopole | 18.06.2019 32 Process Requirements Screening Bench Scale Process Simulation Bench/Pilot Scale Implementation Large Scale Scale Down Strategy Troubleshooting
  • 33. Plan your visit today. EMDMillipore.com/mlab
  • 34. The vibrant M and M Lab are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. © 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.